CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Sirtex Medical Limited is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Sirtex Medical Limited
L 33 101 Miller St
Phone: +61 299648400p:+61 299648400 NORTH SYDNEY, NSW  2060  Australia Ticker: SRXSRX

This company is no longer actively traded on any major stock exchange.

Business Summary
Sirtex Medical Limited is a medical device company with primary objective of manufacturing and distributing liver cancer treatments utilizing small particle technology to markets in Asia-Pacific; Europe, the Middle East and Africa (EMEA), and North and South America. The Company's segments include Asia Pacific, Americas and EMEA. Its lead product is SIR-Spheres Y-90 resin microspheres, which is a targeted radioactive treatment for liver cancer. The treatment is called Selective Internal Radiation Therapy (SIRT) and consists of a minimally invasive surgical procedure performed by an interventional radiologist. The SIR-Spheres microspheres lodge in the small blood vessels of the tumor where they destroy it from the inside while sparing the surrounding healthy tissue. The Company is also engaged in conducting other studies, which include SIRFLOX and FOXFIRE Global for liver metastases, and RESIRT for primary renal cell carcinoma. SIR-Spheres is available in over 40 countries.
(Source: ARS)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/20186/30/2018Yes---Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chief Executive Officer, Executive Director AndrewMcLean 6/16/2017 6/5/2017
Chief Financial Officer, Company Secretary DarrenSmith 2/26/2009 6/30/2008
Executive Vice President of Sales and Marketing,EMEA AnthonyDixon 1/13/2017 1/13/2017
6 additional Officers and Directors records available in full report.

Business Names
Business Name
SIRTeX Medical Limited
SRX

General Information
Stock Exchange: ASX
Fax Number: +61 299648410


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023